Discovery and Development of Therapeutics from Natural Products Against Neglected Tropical Diseases PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Discovery and Development of Therapeutics from Natural Products Against Neglected Tropical Diseases PDF full book. Access full book title Discovery and Development of Therapeutics from Natural Products Against Neglected Tropical Diseases by Goutam Brahmachari. Download full books in PDF and EPUB format.
Author: Goutam Brahmachari Publisher: Elsevier ISBN: 0128157240 Category : Medical Languages : en Pages : 458
Book Description
Discovery and Development of Therapeutics from Natural Products against Neglected Tropical Diseases draws together research on medicinal agents from natural sources as starting points for the design of drugs against Neglected Tropical Diseases (NTDs). From the prediction of promising leads and identification of active agents, to the extraction of complex molecules, the book explores novel, economical and efficacious therapeutics for these diseases. It describes current research and the role of natural products, antimalarial compounds from marine natural products and sesquiterpene lactones, natural antileprotic agents, natural products with potential against Leishmaniasis, Trypanosomiasis and Dengue, and more. In addition, Quinoline and Isoquinoline alkaloids for developing new antiprotozoal agents are discussed, alongside anti-trypanosomatid heterocyclic compounds as structures for development. Combining the expertise of specialists from around the world, this volume aims to support and encourage researchers in the investigation of natural sources as starting points for the development of novel, safe and effective agents for use against neglected tropical diseases. Includes chapters written by active researchers and leading global experts deeply engaged in the research field of natural product chemistry for drug discovery Draws together cutting-edge research advances in natural product chemistry that are targeted at neglected tropical diseases Highlights the future potential of natural products as sources of novel medicinal compounds against neglected tropical diseases
Author: Goutam Brahmachari Publisher: Elsevier ISBN: 0128157240 Category : Medical Languages : en Pages : 458
Book Description
Discovery and Development of Therapeutics from Natural Products against Neglected Tropical Diseases draws together research on medicinal agents from natural sources as starting points for the design of drugs against Neglected Tropical Diseases (NTDs). From the prediction of promising leads and identification of active agents, to the extraction of complex molecules, the book explores novel, economical and efficacious therapeutics for these diseases. It describes current research and the role of natural products, antimalarial compounds from marine natural products and sesquiterpene lactones, natural antileprotic agents, natural products with potential against Leishmaniasis, Trypanosomiasis and Dengue, and more. In addition, Quinoline and Isoquinoline alkaloids for developing new antiprotozoal agents are discussed, alongside anti-trypanosomatid heterocyclic compounds as structures for development. Combining the expertise of specialists from around the world, this volume aims to support and encourage researchers in the investigation of natural sources as starting points for the development of novel, safe and effective agents for use against neglected tropical diseases. Includes chapters written by active researchers and leading global experts deeply engaged in the research field of natural product chemistry for drug discovery Draws together cutting-edge research advances in natural product chemistry that are targeted at neglected tropical diseases Highlights the future potential of natural products as sources of novel medicinal compounds against neglected tropical diseases
Author: David C. Swinney Publisher: John Wiley & Sons ISBN: 3527808620 Category : Medical Languages : en Pages : 392
Book Description
A drug discovery reference to the crippling tropical diseases that affect more than 1 billion people. Neglected Tropical Diseases is the first book of its kind to offer a guide that follows the World Health Organization?s list of neglected tropical diseases. The authors?all are experts on the topic?address the development of effective treatments for 12 crippling infectious diseases that affect almost 20% of the world?s popluation. The book includes information on the common approaches and the most important factors that lead to the development of new drugs for treating tropical diseases. Individual chapters review 12 neglected tropical diseases that are grouped by infectious agent, from viruses to bacteria to eukaryotic parasites. For each of these diseases, the book explains the unmet medical need and explores the current and potential drug discovery strategies. The book also includes information on potential drug compounds derived from natural products. This important book: -Ties together information from different sources for developing novel treatsments forneglected tropical diseases -Is aligned with WHO?s initiative to eradicate tropical diseases -Outlines current and potential drugs for treating tropical diseases -Provides a standard reference for the entire field Written for medicinal chemists, pharmaceutical chemists, pharmaceutical industry, virologists, parasitologists, and specialists on tropics medicine, Neglected Tropical Diseases offers an essential guide and a systematic reference for the development of successful treatments for 12 crippling infectious diseases.
Author: Muhammad Akram Publisher: John Wiley & Sons ISBN: 1119617154 Category : Science Languages : en Pages : 624
Book Description
NEGLECTED TROPICAL DISEASES AND PHYTOCHEMICALS IN DRUG DISCOVERY Explore novel drug discovery updates from medicinal plants to help fight the devastating effects of neglected tropical diseases Neglected Tropical Diseases and Phytochemicals in Drug Discovery delivers a comprehensive exploration of the drug discovery process as it pertains to neglected tropical diseases. The book covers recent advancements in drug discovery, as well as druggable targets and new challenges facing the industry. It offers readers expansive discussions of specific diseases, including protozoan, helminth, bacterial, viral, fungal, and ectoparasitic infections. This book provides readers with insightful perspectives from leading industry voices on fifty years of trends and progress in the search for new, safe, and affordable therapeutic drugs in the fight against neglected tropical diseases. It includes information beneficial to researchers in a variety of fields of biology, chemistry, medicine, and pharmaceuticals. The distinguished authors cover topics including the effects of phytochemicals on the causative agent of leprosy and the potential applicability of phytochemicals in the management of Dengue fever. Readers will also enjoy the inclusion of: Thorough introductions to neglected tropical diseases, phytochemicals, protein targets, and mechanisms in drug discovery, as well as the epidemiology of neglected tropical diseases An exploration of novel bioactive lead compounds for drug discovery against neglected tropical diseases, leishmaniasis, lymphatic filariasis, trypanosomiasis, and schistosomiasis Discussions of protozoan infections, including herbal, nutritional, and traditional remedies for giardiasis and the anti-leishmanial potentials of phytochemicals Examinations of helminth infections, including the prospects of phytochemicals in the treatment of helminthiasis Perfect for medicinal chemists, drug developers, and research and development scientists, Neglected Tropical Diseases and Phytochemicals in Drug Discovery will also earn a place in the libraries of toxicologists and researchers in biology, chemistry, medicinal chemistry, ethnobotany, and bioinformatics seeking a one-stop resource for drug discovery for neglected tropical diseases.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309158060 Category : Medical Languages : en Pages : 442
Book Description
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Author: J. Mulzer Publisher: Springer Science & Business Media ISBN: 3662040425 Category : Medical Languages : en Pages : 363
Book Description
Natural Products have been important sources of useful drugs from prehistoric times to the present. This book gives an overview about this field and provides important recent contributions to the discovery of new drugs generated by research on natural products. Total synthesis of natural products with interesting biological activities is paving the way for the preparation of new and improved analogs. The methods of combinatorial chemistry permit the selection of the best drug from a large number of candidates. Beyond synthesis and evaluation of organic molecules a number of new bioorganic methods are coming to the fore and will be discucced in this isue of the ERnst schering Research Foundation workshop proceedings.
Author: Goutam Brahmachari Publisher: Elsevier ISBN: 0128096926 Category : Medical Languages : en Pages : 334
Book Description
Discovery and Development of Antidiabetic Agents from Natural Products brings together global research on the medicinal chemistry of active agents from natural sources for the prevention and treatment of diabetes and associated disorders. From the identification of promising leads, to the extraction and synthesis of bioactive molecules, this book explores a range of important topics to support chemists in the discovery and development of safer, more economical therapeutics that are desperately needed in response to this emerging global epidemic. Beginning with an overview of bioactive chemical compounds from plants with anti-diabetic properties, the book goes on to outline the identification and extraction of anti-diabetic agents and antioxidants from natural sources. It then explores anti-diabetic plants from specific regions before looking more closely at the background, isolation, and synthesis of key therapeutic compounds and their derivatives, including Mangiferin, Resveratrol, natural saponins, and alpha-glucosidase enzyme inhibitors. The book concludes with a consideration of current and potential future applications. Combining the expertise of specialists from around the world, this volume aims to support and encourage medicinal chemists investigating natural sources as starting points for the development of standardized, safe, and effective antidiabetic therapeutics. Contains chapters written by active researchers and leading global experts who are deeply engaged in the research field of natural product chemistry for drug discovery Provides comprehensive coverage of cutting-edge research advances in the design of medicinal natural products with potential as preventives and therapeutics for diabetes and related metabolic issues Presents a practical review of the identification, isolation, and extraction techniques that help support medicinal chemists in the lab
Author: Goutam Brahmachari Publisher: Elsevier ISBN: 0128169931 Category : Science Languages : en Pages : 332
Book Description
Discovery and Development of Anti-inflammatory Agents from Natural Products, the latest volume in the Natural Product Drug Discovery series, presents cutting-edge research advances in the field of bioactive natural products and natural drug formulations, with this volume focusing on molecules of natural origin and their synthetic analogues that have the potential to act against the pathogens responsible for inflammatory diseases. All aspects of each are covered, including isolations and structure elucidations, in vitro and in vivo biological activity, synthetic optimization, investigations of pharmacodynamics and kinetics, and the structure-activity relationships of anti-inflammatory natural products. Written by active researchers and leading experts, this book brings together an overview of current discoveries and trends in this field. It will be a valuable resource for researchers working to discover promising leads for the development of pharmaceuticals in the prevention and treatment of anti-inflammatory diseases. Features contributions from active researchers and leading experts working in medicinal natural products and herbal formulations Includes recent, cutting-edge advances on medicinal natural products, along with preventative therapies for different kinds of inflammation-directed diseases Offers an authoritative source of information on the industrial application of natural products for medicinal purposes
Author: World Health Organization Publisher: World Health Organization ISBN: 9241515430 Category : Business & Economics Languages : en Pages : 228
Book Description
This report is structured in five parts: national framework for traditional and complementary medicine (T&CM); product regulation; practices and practitioners; the challenges faced by countries; and finally the country profiles. Apart from the section on practices and practitioners the report is consistent with the format of the report of the first global survey in order to provide a useful comparison. The section on practices and practitioners which covers providers education and health insurance is a new section incorporated to reflect the emerging trends in T&CM and to gather new information regarding these topics at a national level. All new information received has been incorporated into individual country profiles and data graphs. The report captures the three phases of progress made by Member States; that is before and after the first WHO Traditional Medicine Strategy (1999?2005) from the first global survey to the second global survey (2005?2012) and from the second survey to the most recent timeline (2012?2018).
Author: World Health Organization Publisher: World Health Organization ISBN: 9241564865 Category : Medical Languages : en Pages : 211
Book Description
"The presence, or absence, of neglected tropical diseases (NTDs) can be seen as a proxy for poverty and for the success of interventions aimed at reducing poverty. Today, coverage of the public-health interventions recommended by the World Health Organization (WHO) against NTDs may be interpreted as a proxy for universal health coverage and shared prosperity - in short, a proxy for coverage against neglect. As the world's focus shifts from development to sustainable development, from poverty eradication to shared prosperity, and from disease-specific goals to universal health coverage, control of NTDs will assume an important role towards the target of achieving universal health coverage, including individual financial risk protection. Success in overcoming NTDs is a "litmus test" for universal health coverage against NTDs in endemic countries. The first WHO report on NTDs (2010) set the scene by presenting the evidence for how these interventions had produced results. The second report (2013) assessed the progress made in deploying them and detailed the obstacles to their implementation. This third report analyses for the first time the investments needed to achieve the scale up of implementation required to achieve the targets of the WHO Roadmap on NTDs and universal coverage against NTDs. INVESTING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES presents an investment strategy for NTDs and analyses the specific investment case for prevention, control, elimination and eradication of 12 of the 17 NTDs. Such an analysis is justified following the adoption by the Sixty-sixth World Health Assembly in 2013 of resolution WHA6612 on neglected tropical diseases, which called for sufficient and predictable funding to achieve the Roadmap's targets and sustain control efforts. The report cautions, however, that it is wise investment and not investment alone that will yield success. The report registers progress and challenges and signals those that lie ahead. Climate change is expected to increase the spread of several vector-borne NTDs, notably dengue, transmission of which is directly influenced by temperature, rainfall, relative humidity and climate variability primarily through their effects on the vector. Investments in vector-borne diseases will avoid the potentially catastrophic expenditures associated with their control. The presence of NTDs will thereby signal an early warning system for climate-sensitive diseases. The ultimate goal is to deliver enhanced and equitable interventions to the most marginalized populations in the context of a changing public-health and investment landscape to ensure that all peoples affected by NTDs have an opportunity to lead healthier and wealthier lives."--Publisher's description.
Author: Anjan Debnath Publisher: Frontiers Media SA ISBN: 2889452484 Category : Languages : en Pages : 179
Book Description
One of the top four contributors to the global burden of disease is diarrheal infections. Intestinal parasites are major causes of morbidity and mortality associated with diarrheal diseases in both the developed and developing world. Amebiasis is responsible for 50 million cases of invasive disease and 70,000 deaths annually in the world. Giardiasis has an estimated worldwide prevalence of 280 million cases annually. In developed countries, Giardia lamblia infects about 2% of adults and 6-8% of children. The prevalence of G. lamblia infection is generally higher in developing countries, ranging from 3% to 90%. Furthermore, giardial infections contribute substantially to the 2.5 million annual deaths from diarrheal disease. In Asia, Africa, and Latin America, about 500,000 new giardiasis cases are reported each year. Cryptosporidium accounts for 20% and 9% of diarrheal episodes in children in developing and developed countries, respectively. Infection with Cryptosporidium can be chronic and especially debilitating in immunosuppressed individuals and malnourished children. A recent study to measure disease burden, based on disability-adjusted life years (DALYs), found that cryptosporidiosis and amebiasis produce about 10.6 million DALYs. This exceeds the DALYs of any helminth infection currently being targeted by the World Health Organization for preventive chemotherapy. Because of its link with poverty, Giardia and Cryptosporidium were included in the WHO Neglected Diseases Initiative in 2004. E. histolytica, G. lamblia, and C. parvum have been listed by the National Institutes of Health (NIH) as category B priority biodefense pathogens due to low infectious dose and potential for dissemination through compromised food and water supplies in the United States. Despite the prevalence of amebiasis, giardiasis, and cryptosporidiosis there are no vaccines or prophylactic drugs. The first-line drugs for invasive amebiasis and giardiasis chemotherapy are nitroimidazoles, with the prototype, metronidazole, being the most common drug used worldwide. Metronidazole has been shown to be both mutagenic in a microbiological system and carcinogenic to rodents, and frequently causes gastrointestinal side effects. In spite of the efficacy of nitroimidazole drugs, treatment failures in giardiasis occur in up to 20% of cases. Clinical resistance of G. lamblia to metronidazole is proven and cross resistance is a concern with all commonly used antigiardial drugs. Nitazoxanide, the only FDA-approved drug for the treatment of cryptosporidiosis, is effective in the treatment of immunocompetent patients and partially effective for immunosuppressed patients. Therefore, it is critical to search for more effective drugs to treat amebiasis, giardiasis, and cryptosporidiosis. This Research Topic for Frontiers in Microbiology will explore the recent progress in drug development for parasitic diarrheal diseases. This includes an understanding of drug resistance mechanisms. We would also welcome submissions on the drug development for other diarrheal parasites. We hope that this research topic will include a comprehensive survey of various attempts by the parasitology research community to create effective drugs for these diseases.